Earlier Detection and Integrated Care Needed for MASLD, T2D Overlap

A new narrative review published in the World Journal of Diabetes is highlighting the complex and bidirectional relationship between metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes (T2D), underscoring the urgent need for improved screening, earlier diagnosis, and more personalized treatment approaches.¹

Formerly classified as non-alcoholic fatty liver disease (NAFLD), MASLD reflects a growing understanding that hepatic fat accumulation is driven primarily by metabolic dysfunction rather than alcohol consumption. The updated terminology emphasizes the central roles of insulin resistance, obesity, dyslipidemia, and systemic inflammation in disease development and progression.

For patients with T2D, the clinical implications are significant, noted the researchers. Epidemiologic data suggest that more than 70% of patients with diabetes exhibit hepatic steatosis, while up to 30% progress to metabolic dysfunction–associated steatohepatitis (MASH), a more severe inflammatory form of the disease characterized by hepatocellular injury and fibrosis. Among these features, fibrosis stage remains the strongest predictor of liver-related morbidity and mortality.

The relationship between MASLD and T2D is mutually reinforcing, the group added. Diabetes accelerates MASLD progression through worsening hepatic steatosis, inflammation, and fibrosis, while MASLD contributes to heightened insulin resistance, systemic inflammation, and increased cardiovascular risk. Cardiovascular disease remains the leading cause of death among patients with MASLD, reflecting shared metabolic mechanisms that extend beyond liver-specific complications.

“MASLD and T2DM represent intersecting global epidemics with substantial clinical and public health implications,” wrote the researchers, who noted “This dual burden underscores the importance of routine liver health assessment within diabetes care and highlights the need for earlier identification of high-risk patients.”

Despite its high prevalence, MASLD often remains underrecognized and undertreated due to its silent clinical course, the researchers highlighted. Liver enzyme levels may remain normal even as fibrosis progresses, complicating early detection. Non-invasive diagnostic tools such as the fibrosis-4 (FIB-4) index, transient elastography, and MRI-based proton density fat fraction have improved risk stratification, though their sensitivity may be reduced in diabetic populations.

Major clinical societies, including the American Diabetes Association and the American Association for the Study of Liver Diseases, now recommend structured MASLD screening for all adults with T2D. A commonly endorsed approach begins with FIB-4 testing followed by elastography for individuals with indeterminate or elevated scores. However, real-world implementation remains inconsistent, emphasizing the need to integrate screening protocols into routine diabetes care workflows.

Lifestyle modification remains the cornerstone of MASLD management across all guidelines. Weight loss of 5% to 10% has been associated with improvements in hepatic steatosis and inflammation, while reductions exceeding 10% may lead to fibrosis regression. Sustained benefit is most consistently achieved through combined dietary intervention and structured aerobic or resistance exercise programs.

Pharmacologic strategies are also evolving. Glucose-lowering agents, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and pioglitazone, have demonstrated improvements in metabolic parameters and liver fat content, though histologic benefits have been inconsistent. In 2024, resmetirom (Rezdiffra; Madrigal) became the first FDA-approved therapy for noncirrhotic MASH with fibrosis, representing a major advance in disease-targeted treatment.²

Looking ahead, combination therapies targeting multiple metabolic and inflammatory pathways are under active investigation.¹ Emerging agents, including fibroblast growth factor analogs, pan-peroxisome proliferator–activated receptor agonists, and thyroid hormone receptor–β agonists, may offer new opportunities to address the multifactorial pathophysiology of MASLD.

References

1. Suresh MG, Mohamed S, Geetha HS, et al. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes. 2026;17(2):113149. doi:10.4239/wjd.v17.i2.113149

2. FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA. Published March 14, 2024. Accessed February 24, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease